Navigation Links
ARIUS announces second quarter fiscal 2008 financial results
Date:7/11/2008

Laureate Pharma Inc. for cGMP manufacturing of humanized

antibody for Phase 1 clinical supply. A cell line producing the

humanized anti-Trop-2 antibody was successfully transferred to

Laureate.

- Preparing for a pre-IND meeting with the FDA.

- ARIUS intends to have clinical trials' materials prepared in the

fourth quarter of 2008 and then a Phase I IND application is expected

to be filed and human clinical trials commenced.

CD59 Complement Inhibitor Program

- Presented a CD59-focused poster at AACR Annual Meeting.

- Generated a cell line producing humanized CD59 antibody that

successfully retained binding characteristics and potent in vivo

activity.

- Preparing to perform preclinical toxicology studies planned for 2008

in preparation for a Pre-IND meeting with the FDA and filing a

Phase I IND application.

CD9 Cancer Stem Cell Program

- Presented a CD9-focused poster at AACR Annual Meeting.

- Presented positive findings demonstrating the ability of the lead

anti-CD9 antibody to kill cancer stem cells in an in vivo model using

cells from human leukemia patients at the American Association of

Cancer Research Special Conference on Cancer Stem Cells in the first

quarter of 2008.

CD63 Antibody Program

- Licensed to Genentech, Inc. in March 2006, the CD63 program continues

to advance in preclinical studies in a variety of cancer indications

as part of a program to move the lead antibody towards the clinic.

Takeda Collaboration

- Discovered and delivered novel antibodies to Takeda. Under the terms

of the research collaboration agreement, ARIUS has successfully met

its obligations to date and has received all scheduled research

payments from Takeda.

Additional Product Updates

- Current
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ARIUS presents new findings for anti-cancer antibody programs at AACR
2. ARIUS announces first quarter fiscal 2008 financial results
3. ARIUS 2008 Annual and Special Meeting of Shareholders
4. ARIUS recognized for entrepreneurial excellence
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how ... latent viruses is the Epstein Barr Virus (EBV), and one ... is a chronic inflammatory disease that destroys the body’s joints. ... patients have high concentrations of EBV DNA in their bodies ...
(Date:1/15/2014)... 15, 2014 AudioNotch is the internet's ... for the treatment of tinnitus. Patients listen to sound ... over a period of weeks to months, their tinnitus volume ... two forms: Notched Music and Notched White Noise. Now, AudioNotch ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Corporation announced today the,release of two major upgrades ... a multilaser capability and the Beta release of ... field well beyond,conventional optical limitations. The Multilaser ... two additional lasers including a 405nm (violet) laser ...
... Nektar,Therapeutics (Nasdaq: NKTR ) today announced the appointment ... reports to Nektar President and,CEO Howard W. Robin, and ... management team. "With his strong understanding of healthcare ... team at Nektar," Robin said. "He brings,significant experience in ...
... 28% over the prior comparable period to A$44.4 ... comparable period to A$4.6 million -- Excluding ... period to A$2.5 million from A$2.0 million -- Reported NPAT ... comparable period including one-off items -- Ellex brand product ...
Cached Biology Technology:Amnis Announces the Release of Multiple Upgrades to the ImageStream(R) System 2Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer 2Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer 3Ellex FY2007 Year End Results 2Ellex FY2007 Year End Results 3
(Date:4/20/2014)... doctors have long known that people with Down syndrome ... (ALL) during childhood, they haven,t been able to explain ... investigators has uncovered a connection between the two conditions. ... journal Nature Genetics , the researchers track the ... in Down syndrome to the cellular havoc that occurs ...
(Date:4/18/2014)... world population predicted to reach 9 billion by ... that considers human-altered landscapes such as farmland, according ... habitat that supports it might be an increasingly ... three-quarters of the land surface is directly affected ... human-caused impacts such as climate change. But what ...
(Date:4/18/2014)... Asteroid and comet impacts can cause widespread ecological ... even global scales. But new research from Brown University ... ancient life at the time of an impact. , ... has found fragments of leaves and preserved organic compounds ... in Argentina. The material could provide a snapshot of ...
Breaking Biology News(10 mins):Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3
... Love," conducted by Syracuse University Professor Stephanie Ortigue, reveals ... same euphoric feeling as using cocaine, but also affects ... in love only takes about a fifth of a ... and an adjunct assistant professor of neurology, both in ...
... at LSU Health Sciences Center New Orleans has found that ... the hormone that regulates water retention in the body on ... for diseases like high blood pressure, congestive heart failure, and ... November 1, 2010 issue of Endocrinology . Daniel Kapusta, ...
... has created a Green Carbon Center to bring the benefits ... other energy sources together in a way that will not ... a means to recycle carbon dioxide into useful products. ... fact is humans are throwing away a potentially valuable resource ...
Cached Biology News:Falling in love 'more scientific than you think,' according to Syracuse University professor 2LSUHSC study IDs proteins regulating water retention in salt-sensitive hypertension 2Green Carbon Center takes all-inclusive view of energy 2Green Carbon Center takes all-inclusive view of energy 3
... cytochrome P450 (CYP450) metabolite postulated to play ... cerebral vasculature. In rat cerebral microvessels, 20-HETE ... vasoconstriction. 20-HETE is excreted mainly as the ... (20-40 pg/ml in human urine) is about ...
... are designed to rapidly and reliably amplify ... APA Technology. APAgene provides hassle-free, ready-to use ... necessary ingredients are provided in each kit. ... for gap filling, localized cloning of genomic ...
Mol wt: average mol wt16,951.27 Da by calculation...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
Biology Products: